MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
MyoKardia and Fulcrum Therapeutics have formed a strategic collaboration to develop targeted therapies for genetic cardiomyopathies. Fulcrum is set to receive an upfront payment of $12.5 million and may earn up to $302.5 million in milestone payments for the first product, with additional potential royalties on net sales. MyoKardia will handle all development and commercialization efforts, leveraging Fulcrum’s proprietary target discovery engine. This partnership aims to address critical patient needs in cardiovascular diseases, emphasizing both companies' strengths in precision medicine.
- Fulcrum to receive $12.5 million upfront payment.
- Potential for up to $302.5 million in milestone payments and additional royalties.
- Collaboration enhances therapeutic development in genetic cardiomyopathies.
- None.
BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and license agreement to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.
Under the agreement, MyoKardia will access Fulcrum’s unique, proprietary target discovery engine to identify therapeutics that control the expression of genes that are known to be underlying drivers of genetic cardiomyopathies. The collaboration focuses joint discovery efforts on certain undisclosed genetic targets. MyoKardia will be responsible for all development and commercialization activities for, and will have global rights to, any potential therapeutics identified through this collaboration.
Fulcrum will receive a payment of
MyoKardia intends to select targets for further exploration under this collaboration informed by its integrated research and development engine, which includes capabilities in translational research, proprietary and novel disease models, clinical development, and patient engagement and identification. Potential diseases associated with such undisclosed targets are expected to share common characteristics with indications currently being pursued by MyoKardia: strong and genetically-validated mechanistic rationale, high unmet patient need, potentially efficient pathway to approval, and synergy with the commercial organization that MyoKardia is building.
“This partnership is a natural extension of MyoKardia’s investments over the last eight years in building a world-leading cardiovascular research, translational, clinical and commercial organization. We believe this collaboration will enable us to leverage our unique strengths to expand thoughtfully in identifying new therapeutic candidates for the potential treatment of heritable cardiomyopathies,” said Robert S. McDowell, Ph.D., MyoKardia’s Chief Scientific Officer. “We have been impressed by Fulcrum’s ability to discover new biology around genetic muscle disorders. By working together, we hope to further our mission to treat patients suffering from serious cardiovascular disease.”
“This collaboration highlights the broad applicability of our product engine to discover and develop new treatments in genetically defined rare diseases with high unmet need,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “We are pleased to partner with MyoKardia, a leader in the field of precision cardiovascular medicine and look forward to leveraging their unique capabilities to rapidly advance potential treatments to serve patients in urgent need.”
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by (1) understanding the biomechanical underpinnings of disease; (2) targeting the proteins that modulate a given condition; (3) identifying patient populations with shared disease characteristics; and (4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates a regulatory filing in the second half of 2020 with FTX-6058 for the treatment of sickle cell disease.
Please visit www.fulcrumtx.com.
| 55%; width: | 45%; width: |
| Michelle Corral | Christi Waarich |
| Executive Director, Corporate Communications and Investor Relations | Director, Investor Relations and |
| MyoKardia, Inc. | Corporate Communications |
| 650-351-4690 | 617-651-8664 |
| ir@myokardia.com | cwaarich@fulcrumtx.com |
| Hannah Deresiewicz (investors) | Stephanie Ascher (investors) |
| Stern Investor Relations, Inc. | Stern Investor Relations, Inc. |
| 212-362-1200 | 212-362-1200 |
| hannah.deresiewicz@sternir.com | stephanie.ascher@sternir.com |
| Julie Normant (media) | Kaitlin Gallagher (media) |
| W2O | Berry & Company Public Relations |
| 628-213-3754 | 212-253-8881 |
| jnormart@w2ogroup.com | kgallagher@berrypr.com |
FAQ
What is the collaboration between Fulcrum Therapeutics and MyoKardia?
What are the financial terms of the Fulcrum and MyoKardia collaboration?
What is MyoKardia's role in the collaboration with Fulcrum?
What diseases are targeted in the Fulcrum and MyoKardia partnership?
How does this collaboration benefit patients with cardiovascular diseases?
